(Q41127616)

27 September 2017

title

Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve (English)

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

18 October 2022

main subject

electroencephalography

1 reference

1 reference

schizophrenic psychology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631250

18 October 2022

author name string

P. Czobor

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631250

18 October 2022

J. Volavka

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1631250

18 October 2022

language of work or name

English

0 references

publication date

1 May 1992

1 reference

full work available at URL

27 September 2017

https://api.elsevier.com/content/article/PII:016517819290077G?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

https://api.elsevier.com/content/article/PII:016517819290077G?httpAccept=text/plain

18 October 2022

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

18 October 2022

1 reference

27 September 2017

volume

42

1 reference

27 September 2017

issue

2

1 reference

27 September 2017

page(s)

129-144

1 reference

Vigilance and Evaluation of Psychotropic Drug Effects on EEG

27 September 2017

cites work

4

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Functional and anatomical brain imaging: impact on schizophrenia research

18 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Pretreatment EEG predicts short-term response to haloperidol treatment

18 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Plasma homovanillic acid as a predictor of response to neuroleptics

18 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine

18 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Use of the Research Diagnostic Criteria and the Schedule for Affective Disorders and Schizophrenia to study affective disorders

18 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

EEG and human psychopharmacology

18 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment

18 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Topographic factor analysis of the EEG with applications to development and to mental retardation

18 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Development of a classification rule for four clinical therapeutic psychotropic drug classes with EEG power-spectrum variables of human volunteers

18 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

A Simple Sequentially Rejective Multiple Test Procedure

18 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Qualitative and Quantitative EEG Findings in Schizophrenia

18 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Digital computer analyzed sleep and resting EEG during haloperidol treatment

18 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Computerized EEG as a Predictor of Drug Response in Treatment Resistant Schizophrenics

18 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Developmental equations for the electroencephalogram.

18 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

18 October 2022

Neurometrics

28

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Neurometrics: computer-assisted differential diagnosis of brain dysfunctions

18 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Computerized EEG in schizophrenia

18 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

The effect of neuroleptics on cognitive and psychomotor function

18 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Mesocorticolimbic dopaminergic network: functional and regulatory roles

18 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Neuroleptic plasma level may predict response in patients who meet a criterion for improvement

18 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Concurrent lithium administration results in higher haloperidol levels in brain and plasma of guinea pigs.

18 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

MANOVA method for analyzing repeated measures designs: an extensive primer.

18 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain

18 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol

18 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy

18 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Research diagnostic criteria: rationale and reliability

18 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

COMSTAT rule for vigilance classification based on spontaneous EEG activity

18 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Prediction of neuroleptic on-drug response in schizophrenic in-patients by EEG

18 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Dopamine and norepinephrine activity in schizophrenia. An integrative perspective

18 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Haloperidol blood levels and clinical effects

18 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

The effects of haloperidol on the EEG spectrum

18 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Central D1- and D2-receptor occupancy during antipsychotic drug treatment

18 October 2022

52

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

18 October 2022

53

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Dopamine receptor occupancy and plasma haloperidol levels

18 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

Drug trials and heterogeneity in schizophrenia: the mean is not the end

18 October 2022

55

1 reference

https://api.crossref.org/works/10.1016/0165-1781(92)90077-G

18 October 2022

Identifiers

1 reference

27 September 2017

1 reference